ANDA 209372, held by Amneal Pharms Co. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 209372 (Doxycycline Hyclate), held by Amneal Pharms Co, was first approved by FDA on Oct 6, 2017, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 6, 2017 | Original application | Approved | None posted |
| Doxycycline HyclateEQ 75MG BASE · tablet;oral | Doxycycline Hyclate | Discontinued |
| Doxycycline HyclateEQ 150MG BASE · tablet;oral | Doxycycline Hyclate | Discontinued |
| Jul 23, 2025 | Supplement 8Labeling · Standard review | Approved | None posted |
| Sep 12, 2023 | Supplement 4Labeling · Standard review | Approved | None posted |
| Oct 10, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 6, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters